

10/538/134

10/936, 134 YONG CHU 6-26-2006

**\$%^STN;HighlightOn=;HighlightOff=;**

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssptaylc1626

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered  
NEWS 5 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records  
NEWS 6 MAY 11 KOREAPAT updates resume  
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAplus  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:46:48 ON 26 JUN 2006

=> le req

LE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY      SESSION  
0.21      0.21

FILE 'REGISTRY' ENTERED AT 09:46:57 ON 26 JUN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9  
DICTIONARY FILE UPDATES: 25 JUN 2006 HIGHEST RN 889359-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.



\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added,   \*  
\* effective March 20, 2005. A new display format, IDERL, is now   \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10936134\10936134.str



chain nodes :

11 12

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 17 18 19 22 23 24 25 26 27

chain bonds :

1-12 10-11 12-13 13-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 4-10 5-6 7-8 8-9 9-10 13-17 13-19 17-18 18-19  
22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

1-2 1-6 1-12 2-3 3-4 4-5 4-7 4-10 5-6 7-8 8-9 9-10 10-11 13-17 13-19

17-18 18-19

exact bonds :

12-13 13-22

normalized bonds :

22-23 22-27 23-24 24-25 25-26 26-27

G1:X,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:Atom 17:Atom 18:Atom 19:Atom 22:Atom 23:Atom 24:Atom  
25:Atom 26:Atom 27:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11  
SAMPLE SEARCH INITIATED 09:47:19 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 4 TO 200  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s 11 full  
FULL SEARCH INITIATED 09:47:30 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 114 TO ITERATE

100.0% PROCESSED 114 ITERATIONS 66 ANSWERS  
SEARCH TIME: 00.00.01

L3 66 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 09:47:35 ON 26 JUN 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2006 VOL 145 ISS 1  
FILE LAST UPDATED: 25 Jun 2006 (20060625/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13  
L4 6 L3

=> d ibib abs hitstr tot



*Current appl.*

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:534204 CAPLUS  
 DOCUMENT NUMBER: 141:89006  
 TITLE: Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists  
 INVENTOR(S): Yang, Hanbiao; Kazmierski, Wieslaw Mieczyslaw;  
 Aquino, Christopher Joseph  
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
 SOURCE: PCT Int. Appl., 130-pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055016	A1	20040701	WO 2003-US39618	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ED, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, 2M, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296992	A1	20040709	AU 2003-296992	20031212
EP 1569933	EP 20050907	EP 2003-813415	20031212	
h: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BE, HU, SK				
JP 2006511552	T2	20060406	JP 2004-560830	20031212
US 2006059284	A1	20060316	US 2005-538134	20050609
PRIORITY APPLN. INFO.: US 2004059284			US 2002-433372P	P 20021213
			WO 2003-US39618	W 20031212

OTHER SOURCE(S): MARPAT 141:89006  
 GI

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I (R1 = (un)substituted-alkyl, -alkynyl, -cycloalkyl, -heterocycl, etc., or R1 and X taken together form a saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, which is fused to ring A; R2 = OH, halogen (un)substituted-alkyl, -alkoxy, -etyl, -heteroaryl, -cycloalkyl, etc., or two geminal R2s are optionally taken together to form a spiro, saturated, partially saturated or aromatic 5-6 membered ring having 0-3 heteroatoms selected from O, P, S, or N, said fused or spiro ring optionally substituted; R3 = H, halo, cyano, trifluoromethyl, (un)substituted amino, acylamino, alkyl; R9 = H or oxo; X = Cl-5 alkyne, optionally substituted with o xo, thioxo, -S(O)t where t = 1 or 2, halogen atoms, or alkyl and optionally containing 1-3 oxygen, nitrogen, sulfur, or phosphorus atoms; Y = carbonyl, thiocarbonyl, 1,2-dioxaethylene, alkyl, alkenyl, etc.; A = saturated, partially saturated, or aromatic 3-7 monocyclic or 8-10 membered bicyclic ring having one ring nitrogen and 0-4 addnl. heteroatoms selected from O, P, S or N; m = 0 or 1, n = 0-5); and their pharmaceutically acceptable salts are prepared and disclosed as CCR5 antagonists. Thus, II was prepared via condensation of tert-Bu-3-(3,4-dichlorophenyl)-3-(3-oxopropyl)pyrrolidine-1-carboxylate (preparation given) with the amine III followed by deprotection and acylation with 2-furanyl chloride. I have pIC50 values of ≥25 in assays for CCR5 antagonism. As CCR5 antagonists, I are useful for the treatment of viral infections (particularly HIV infection).  
 IT 716326-63-5P 716326-64-6P 716326-65-7P  
 IT 716326-66-8P 716326-67-9P 716326-68-0P

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

716326-69-1P 716326-70-4P 716326-71-5P  
 716326-72-6P 716326-73-7P 716326-74-8P  
 716326-75-9P 716326-76-0P 716326-77-1P  
 716326-78-2P 716326-79-3P 716326-80-4P  
 716326-81-7P 716326-82-8P 716326-83-9P  
 716326-84-0P 716326-94-2P 716326-95-3P  
 716326-96-9P 716326-97-5P 716326-98-6P  
 716326-99-7P 716327-00-3P 716327-01-4P  
 716327-02-5P 716327-03-6P 716327-04-7P  
 716327-05-8P 716327-06-9P 716327-07-0P  
 716327-08-1P 716327-09-2P 716327-10-3P  
 716327-11-6P 716327-12-7P 716327-13-8P  
 716327-14-9P 716327-15-0P 716327-16-1P  
 716327-17-2P 716327-18-3P 716327-19-4P  
 716327-20-5P 716327-21-6P 716327-22-9P  
 716328-43-7P

PL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RP: prep. of pyrrolidine and azetidine derivs. as CCR5 antagonists


RN 716326-63-5 CAPLUS

CN 1-Pyrrolidinocarboxylic acid,


3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-

1,3,8-triazaspiro[4.5]dec-8-yl)propyl-, 1,1-dimethylethyl ester (9CI)

(CA INDEX NAME)



RN 716326-64-6 CAPLUS  
 CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716326-65-7 CAPLUS  
 CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 716326-64-6  
 CMF C31 H34 Cl2 N4 O3




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2

F-C(=O)CO2H

RN 716326-66-8 CAPLUS

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(5-isoxazolylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716326-67-9 CAPLUS

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(5-isoxazolylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 716326-66-8



CM 2


CRN 76-05-1  
CMF C2 H F3 O2

RN 716326-68-0 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(1H-pyrrol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 716326-69-1 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(1H-pyrrol-2-ylcarbonyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 716326-68-0  
CMF C31 H35 C12 N5 O2


CM 2

CRN 76-05-1  
CMF C2 H F3 O2

RN 716326-70-4 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(1-oxopentyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 716326-71-5 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716326-72-6 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 716326-71-5  
CMF C32 H33 C12 F3 N4 O3

CM 2


CRN 76-05-1  
CMF C2 H F3 O2

RN 716326-73-7 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 716326-74-8 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[4-oxo-1-[3-(trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 716326-73-7  
CMF C32 H37 C12 F3 N4 O2


CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 716326-75-9 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(1-oxopentyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-76-0 CAPLUS  
CN Pyrrolidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-77-1 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716326-78-2 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-77-1


CMF C31 H38 Cl2 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2

RN 716326-79-3 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716326-80-6 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-79-3  
CMF C32 H40 Cl2 N4 O2


CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 716326-81-7 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-acetyl-8-[3-(1-acetyl-3-(3,4-dichlorophenyl)-3-pyrrolidinyl)propyl]-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 716326-82-8 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-acetyl-8-[3-(1-acetyl-3-(3,4-dichlorophenyl)-3-pyrrolidinyl)propyl]-1-(3-methylphenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 716326-81-7


CMF C31 H38 Cl2 N4 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 716326-83-9 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-(1-(2-benzoxazolyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl)propyl]-1-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)



RN 716326-84-0 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-(1-(2-benzoxazolyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl)propyl]-1-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 716326-83-9  
CMF C33 H35 Cl2 N5 O2



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

RN 716326-94-2 CAPLUS  
CN Azetidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 716326-95-3 CAPLUS  
CN Formic acid, compd. with  
3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(phenylsulfonyl)azetidine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 716326-94-2  
CMF C31 H34 Cl2 N4 O3 S


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 716326-99-7 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-1-(1H-pyrazol-4-ylcarbonyl)- (9CI) (CA INDEX NAME)



RN 716327-00-3 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-[(5-(1,1-dimethylethyl)-2-furanyl)carbonyl]-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716327-01-4 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-(3-(3,4-dichlorophenyl)-1-(4,5-dihydro-1H-imidazol-2-yl)-3-pyrrolidinyl)propyl)-1-phenyl- (9CI) (CA INDEX NAME)




CM 2

CRN 64-18-6  
CMF C H2 O2


RN 716326-96-4 CAPLUS  
CN Azetidine, 3-(3,4-dichlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716326-97-5 CAPLUS  
CN Azetidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716326-98-6 CAPLUS




RN 716327-02-5 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 716327-03-6 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]propyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 716327-04-7 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-(trifluoromethyl)phenyl)-1,3,8-triazaspiro[4.5]dec-8-yl]propyl)-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 716327-05-6 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[1-(2-benzothiazolyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 716327-06-9 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[1-(1H-benzimidazol-2-yl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 716327-07-0 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-(1-(3-methylphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl)propyl]-1-(1-oxpentyl)- (9CI) (CA INDEX NAME)




RN 716327-08-1 CAPLUS  
CN Pyrrolidine, 1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 716327-09-2 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl]propyl]-1-(1-oxpentyl)- (9CI) (CA INDEX NAME)




RN 716327-10-5 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(5-isoxazolylcarbonyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 716327-11-6 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-(cyclobutylcarbonyl)-8-[3-(1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl)propyl]-1-(3-trifluoromethylphenyl)- (9CI) (CA INDEX NAME)




RN 716327-12-7 CAPLUS  
CN Pyrrolidine, 3-(3,4-dichlorophenyl)-1-(3-methyl-1-oxobutyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)




RN 716327-13-8 CAPLUS  
CN Pyrrolidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 716327-14-9 CAPLUS  
CN 1-Pyrrolidinedicarboximide acid, N-cyano-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methoxyphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl]propyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 716327-15-0 CAPLUS  
CN Pyrrolidine, 1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-[3-[1-(3-methylphenyl)-4-oxo-1,3,8-triaspiro[4.5]dec-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 716327-16-1 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-(cyclopentylcarbonyl)-8-[3-(1-(cyclopentylcarbonyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl)propyl]-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 716327-17-2 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-(cyclobutylcarbonyl)-8-[3-[1-(cyclobutylcarbonyl)-3-(3,4-dichlorophenyl)-3-pyrrolidinyl]propyl]-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 716327-18-3 CAPLUS  
CN Pyrrolidine, 3-(4-chlorophenyl)-1-(cyclobutylcarbonyl)-3-[3-[4-oxo-1-(3-trifluoromethyl)phenyl]-1,3,8-triazaspiro[4.5]dec-8-yl]propyl- (9CI) (CA INDEX NAME)




RN 716327-19-4 CAPLUS  
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-[3-(3,4-dichlorophenyl)-1-(1-oxopentyl)-3-pyrrolidinyl]propyl]-3-(1-oxopentyl)-1-(3-trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)




RN 716327-20-7 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 716327-21-8 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 716327-22-9 CAPLUS  
CN Pyrrolidine, 3-(3-chlorophenyl)-1-(2-furanylcarbonyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



RN 716328-43-7 CAPLUS  
CN Pyrrolidine, 1-acetyl-3-(3,4-dichlorophenyl)-3-[3-(1-(3-methylphenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TITLE: Investigation of SAR requirements of SR 142801 through

AUTHOR(S): Ravaglià, Luca F.; Vitali, Mauro; Artico, Marco; Gragnani, Davide; Hay, Douglas W. P.; Luttmann, Mark A.; Mena, Renzo; Pifferi, Giorgio; Giardina, Giuseppe A. M.

CORPORATE SOURCE: Department of Medicinal Chemistry, SmithKline Beecham S.p.A., Milan, 20021, Italy

SOURCE: European Journal of Medicinal Chemistry (1999)

PUBLISHER: Editions Scientifiques et Médicales Elsevier

DOCUMENT TYPE: Journal LANGUAGE: English

AB To rapidly gain information on structure-activity relation (SAR) requirements of the human neurokinin 3 (hNK-3) receptor antagonist SR 142801, an indexed combinatorial library was synthesized in solution and screened on the hNK-3 receptor. SAR considerations drawn from binding


of a pool of combinatorial mixts. were confirmed through the synthesis and bioassay evaluation of some individual compds.

IT 256497-28-6 RD: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Structure-activity relation requirements of SR 142801 as neurokinin 3 receptor antagonists through indexed combinatorial library in

solution)

RN 256497-28-6 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-(3,4-dichlorophenyl)-3-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1998:689192 CAPLUS  
 DOCUMENT NUMBER: 129:330656  
 TITLE: Preparation of 1-(3-pyrrolidinylalkyl)-4-piperidinecarboxamides as tachykinin antagonists  
 INVENTOR(S): Burkholder, Timothy P.; Kudlacek, Elizabeth M.; Le Tieu-binh; Maynard, George D.  
 PATENT ASSIGNEE(S): Hoechst Marion Roussel Inc., USA  
 SOURCE: U.S., 93 pp., Cont.-in-part of U.S. 5,635,510.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5824690	A	19981020	US 1997-798664	19970211
CA 2,140,709	A	19980112	CA 1994-3091	19940204
US 5635510	A	19970603	US 1994-332027	19941031
			US 1993-58606	B2 19930506
			US 1994-225371	B2 19940419
			US 1994-332027	A2 19941031

OTHER SOURCE(S): MARPAT 129:330656  
 GI



AB Title compds. (I; R = G2(CH2)nR2; G1,G2 = CH2 or CO; R1 = (un)substituted Ph, -naphthyl, pyridyl, etc.; R2 = (un)substituted Ph or -pyridyl; Y1 = CONHRS or CONR6R7; R5 = H, alkyl, (CH2)qNR6R7, etc.; R6,R7 = alkyl; NR6R7 = heterocycl; Y2 = (un)substituted phenyl(methyl), -pyridyl, -thienyl; Y1Y2 = atoms to complete a ring; Z = (CH2)2-3; n = 0 or 1; q = 2 or 3) were prepared. Thus, 3,4-C12C6H3CH2CN was biscondensed with BrCH2CO2Et

and the reduced product cyclized to give, after reduction and N-benzylation, 1-benzoyl-3-(2-hydroxyethyl)-3-(3,4-dichlorophenyl)pyrrolidine. The latter was treated with MeSO2Cl and the product aminated by (I) phenylpiperidine-4-carboxamide (preparation given) to give I (GI =

CH2; R = C6H5Cl2-3,4, Y1 = CONH2, Y2 = Ph, Z = CH2CH2). Data for biol. activity of I were given.


IT 167261-54-3P 167261-55-4P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ETO (Biological study); PREP (Preparation); USES (Uses); (preparation of 1-(3-pyrrolidinylalkyl)-4-piperidinecarboxamides as tachykinin antagonists)

RN 167261-54-3 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Pyrrolidine,  
 3-(3,4-dichlorophenyl)-1-(2-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 167261-55-4 CAPLUS  
 CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1998:604661 CAPLUS  
 DOCUMENT NUMBER: 129:245045

TITLE: Preparation of 3,3-disubstituted piperidines for treating the conditions associated with an excess of tachykinins

INVENTOR(S): Harrison, Timothy; Swain, Christopher John

PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK

SOURCE: U.S., 17 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5807865	A	19980915	US 1996-733482	19961018
PRIORITY APPLN. INFO.:			GB 1995-21781	19951024

OTHER SOURCE(S): MARPAT 129:245045  
 GI



AB The title compds. (I; m = 0-3; n = 1-3 (with the proviso that the sum of m+n = 1-4); X = CR1R2; one of Y, Z = O while the other = H2; Ar = (un)substituted Ph, thienyl, benzothienyl, etc.; R = (un)substituted Ph; R1R2 = (un)substituted 5-6 membered non-aromatic ring which may contain

1-2 groups of NRS, etc.; R5 = H, C1-4 alkyl, etc.), useful in the treatment or prevention of neuropathy, asthma, osteoarthritis, rheumatoid arthritis or pain. Compds. I were prepared. Thus, reaction of 5-(3-methanesulfonyloxypropyl)-5-(3,4-dichlorophenyl)-1-benzylpiperidin-2-one with 4-acetyl-4-phenylpiperidine-HCl in the presence of K2CO3 in DMF afforded 41% I (Y = O; Z = H2; R = Ph; Ar = 3,4-C12C6H3; n = 1; m = 2; X = CR1R2; R1 = Ph; R2 = MeC(O)). Compds. I are effective at 0.05-10 mg/kg/day in the treatment of the conditions associated with an excess of tachykinins.

IT 213180-01-9P


RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); ETO (Biological study); PREP (Preparation); USES (Uses); (preparation of 3,3-disubstituted piperidines for treating the conditions

associated with an excess of tachykinins)

RN 213180-01-9 CAPLUS

CN Piperidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-(3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

(103(a))  
 6-mercapto r.y

ACCESSION NUMBER: 1997:375289 CAPLUS  
 DOCUMENT NUMBER: 127:95200  
 TITLE: Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists  
 INVENTOR(S): Burkholder, Timothy P.; Kudlacz, Elizabeth N.; Maynard, George D.  
 PATENT ASSIGNEE(S): Merrell Pharmaceuticals Inc., USA  
 SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 225,371, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5675181	A	19970603	US 1994-332027	19941031
CN 1124261	A	19960619	CN 1994-192362	19940422
CN 1081635	B	20020327		
ZA 9403091	A	19950112	ZA 1994-3091	19940504
US 5608356	A	19970715	US 1995-477167	19950607
US 5621416	A	19990119	US 1997-795576	19970206
US 5843930	A	19981020	US 1997-798664	19970211
PRIORITY APPLN. INFO.:			US 1993-58606	B2 19930506
			US 1994-225371	B2 19940419
			US 1994-332027	A3 19941031


OTHER SOURCE(S): MARPAT 127:95200  
 GI




AB The invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines  
 I

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 [G, G1 = CH2, CO; m = 2, 3; n = 0, 1; Ar1 = (un)substituted Ph, naphthyl, pyridyl, thiienyl, or benzo[1,3]dioxan-5-yl; Ar2 = (un)substituted Ph or pyridyl; Y1 = (un)substituted Ph, naphthyl, pyridyl, thiienyl, or CH2Ph; or Y1Y2 = atoms to complete certain Ph-substituted, 5-membered, diazapirro ring fusions], their stereoisomers, N-oxides, and pharmaceutically acceptable salts, and processes for prepn. of the same. I are useful for their pharmacol. activities, such as tachykinin antagonism, and esp. substance P and neuropeptide A antagonism. Such compds. are indicated for conditions assocd. with neurogenic inflammation and other diseases. For instance, 3-(3,4-dichlorophenyl)-3-(2-hydroxyethyl)pyrrolidine underwent a sequence of amidation with 3,4,5-trimethoxybenzyl chloride (71%), conversion of the alc. to a methanesulfonate ester (92%), and reaction of the mesylate moiety with 4-phenylpiperidine-4-carboxamide-HCl (71%), to give title compd. II. In an assay for modulation of NKA-induced respiratory effects in guinea pigs, II at 10 mg/kg reduced dyspnea to 60% of control.

IT 167261-54-3P 167261-55-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);  
 (preparation of pyrrolidinylalkylpiperidines as tachykinin antagonists)  
 RN 167261-54-3 CAPLUS  
 CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 167261-55-4 CAPLUS  
 CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1995:772578 CAPLUS  
 DOCUMENT NUMBER: 123:198629


TITLE: Preparation of substituted (pyrrolidin-3-ylalkyl)piperidines as tachykinin antagonists  
 INVENTOR(S): Burkholder, Timothy P.; Le, Tieu-Binh; Kudlacz, Elizabeth M.; Maynard, George D.  
 PATENT ASSIGNEE(S): Merrell Dow Pharmaceuticals Inc., USA  
 SOURCE: PCT Int. Appl., 238 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426735	A1	19941124	WO 1994-US4498	19940422
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MN, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2160462	AA	19941124	CA 1994-2160462	19940422
CA 2160462	C	19981215		
AU 9469426	A1	19941212	AU 1994-69426	19940422
AU 678023	B2	19970515		
EP 696280	A1	19960214	EP 1994-917898	19940422
EP 696280	B1	19970924		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
SE HU 74085	A2	19961128	HU 1995-3153	19940422
JP 09500361	T2	19970114	JP 1994-525453	19940422
JP 3424174	B2	20030707		
AT 158580	E	19971015	AT 1994-917898	19940422
ES 2110761	T3	19980216	ES 1994-917898	19940422
IL 109496	A1	20000726	IL 1994-109496	19940502
ZA 9403091	A	19950112	ZA 1994-3091	19940504
FI 9505258	A	19951130	FI 1995-5258	19951102
FI 113047	B1	20040227		
NO 9504400	A	19960108	NO 1995-4400	19951103
NO 309144	B1	20001218		
PRIORITY APPLN. INFO.:			US 1993-58606	A 19930506
			US 1994-218483	A 19940328
			US 1994-225371	A 19940419
			WO 1994-US4498	W 19940422


OTHER SOURCE(S): MARPAT 123:198629  
 GI






RN 167261-19-3 CAPLUS  
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triaspiro[4.3]deca-8-yl)ethyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 167261-20-6 CAPLUS  
CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triaspiro[4.3]deca-8-yl)ethyl]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



AB Title compds. I (G1 = CH<sub>2</sub>, CO; m = 2,3; n = 0,1; Ar1 = V3  
 (substituted)aryl, (substituted)heterocycl; Ar2 = (substituted)Ph or  
 heterocycl); Y1 = (substituted)HNCO, (dialkylamino)carbonyl,  
 N-heterocyclylcarbonyl; Y2 together with the C to which they are  
 attached

form a substituted spirocyclic, or stereoisomers, or salts thereof, are  
 prepared. I are claimed for treatment of neurogenic inflammation.  
 (CA INDEX NAME)

~~Agthi... pain... and cough~~ I-3-(3,4-Dichlorophenyl)-3-(2-hydroxyethyl)pyrrolidine (preparation given) was reacted with

2,4-dimethoxybenzoyl chloride to give 3-(3,4-dichlorophenyl)-1-(2,4-dimethoxybenzoyl)-3-(2-hydroxyethyl)pyrrolidine which in 2 steps was

converted to I (G1 = H<sub>2</sub>C, G2 = CO, m = 2, n = 0, Ar1 = 3,4-C12C6H3, Ar2 = 2,4-(MeO)2C6H3, Y1 = H2NCO, Y2 = Ph). Tachykinin antagonist was

demonstrated.

IT 167261-54-3P 167261-55-4P 167261-86-1P

167261-87-2P 167261-88-3P 167261-89-4P

167261-90-7P 167261-91-8P 167262-05-7P

167262-06-8P 167262-19-3P 167262-20-6P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted (pyrrolidinylalkyl)piperidines as

tachykinin


antagonists)

RN 167261-54-3 CAPLUS

CN Pyrrolidine,

3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-


phenyl)-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl - (9CI) (CA INDEX NAME)



RN 167261-55-4 CAPLUS

CN Pyrrolidine, 1-benzoyl-3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1-phenyl)-1,3,8-


triazaspiro[4.5]dec-8-yl]ethyl - (9CI) (CA INDEX NAME)



RN 167261-86-1 CAPLUS

CN Pyrrolidine,


3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-1-(3,4,5-trimethoxybenzoyl) - (9CI) (CA INDEX NAME)



RN 167261-87-2 CAPLUS

CN Pyrrolidine,


3-(3,4-dichlorophenyl)-3-[2-(4-oxo-1,3,8-triazaspiro[4.5]dec-1-en-8-yl)ethyl]-1-(3,4,5-trimethoxybenzoyl) - (9CI) (CA INDEX NAME)



RN 167261-88-3 CAPLUS

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(4-fluorophenyl)-2-(4-oxo-1-

3,8-triazaspiro[4.5]dec-8-yl)ethyl]-1-(3,4,5-trimethoxybenzoyl) - (9CI) (CA INDEX NAME)




RN 167261-89-4 CAPLUS

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(4-fluorophenyl)-2-(4-oxo-3-(phenylmethyl)-1,3,8-

triazaspiro[4.5]dec-8-yl)ethyl]-1-(3,4,5-

trimethoxybenzoyl) - (9CI) (CA INDEX NAME)




RN 167261-90-7 CAPLUS

CN Pyrrolidine,

3-(3,4-dichlorophenyl)-3-[2-(2,4-dioxo-3-(phenylmethyl)-1,3,8-

triazaspiro[4.5]dec-8-yl)-2-(4-fluorophenyl)ethyl]-1-(3,4,5-

trimethoxybenzoyl) - (9CI) (CA INDEX NAME)




RN 167261-91-8 CAPLUS

CN Pyrrolidine, 3-(3,4-dichlorophenyl)-3-[2-(2,4-dioxo-1,3,8-

triazaspiro[4.5]dec-8-yl)-2-(4-fluorophenyl)ethyl]-1-(3,4,5-

trimethoxybenzoyl) - (9CI) (CA INDEX NAME)




RN 167262-05-7 CAPLUS

CN Pyrrolidine,

3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-

phenyl)-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl - (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 167262-06-8 CAPLUS

CN Pyrrolidine,

3-(3,4-dichlorophenyl)-1-(2,6-dimethoxybenzoyl)-3-[2-(4-oxo-1-

phenyl)-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl - (-)- (9CI) (CA INDEX NAME)

Rotation (-).

